Skip to content

Home - Media - Press releases    
Latest press releases
14 May 2008
FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder.  
8 May 2008
AstraZeneca Submits sNDA for Seroquel XR™ for the Treatment of Generalised Anxiety Disorder – a First for the Atypical Antipsychotic Class of Medicines
AstraZeneca today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder (GAD), including maintenance of antianxiety effect. It is the first time approval has been sought for an atypical antipsychotic medicine in GAD.  
6 May 2008
EPO Announces Symbicort® European COPD Use Patent Decision
AstraZeneca today announced that the European Patent Office (EPO) Technical Board of Appeal has made a final ruling that the European Combination patent covering the use of Symbicort® (formoterol and budesonide) for the treatment of chronic obstructive pulmonary disease (COPD) (EPB1014993) has been revoked, following an appeal from generic manufacturers Norton Healthcare and Generics UK.  
2 May 2008
AstraZeneca Files Marketing Application in Europe for EGFR Inhibitor Gefitinib (IRESSA™) in Locally Advanced Pre-Treated Non-Small Cell Lung Cancer
AstraZeneca today announced the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for its oral anti-cancer drug, gefitinib (IRESSA™) as a treatment for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have been pre-treated with platinum-containing chemotherapy.  
30 April 2008
AstraZeneca Submits sNDA for SYMBICORT® for COPD Treatment
AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
  
24 April 2008
AstraZeneca PLC First Quarter Results 2008
"Underlying business performance on track to achieve full year financial targets. Core EPS target increased to reflect year to date currency impact."  
^Back to top
AstraZeneca websites
Search
Quick links
Email alerts

Receive email notification for news, events & presentations via our email alert service
Order a report

Online order form
  Tel: +44 (0)1707 256 677
AstraZeneca news feed
 Terms of use  Privacy policy    © AstraZeneca PLC 2003 - 2008